Associated tags: Radiopharmaceutical, JPL, Choice, Health, Pharmaceutical, Jubilant, Hospitals, PET, Biotechnology, Hospital, Patient, Society, Learning, Radiology, Cardiology
Locations: USA, EUROPE, SINGAPORE
Retrieved on:
Friday, September 29, 2023
Hospitals,
Health,
Radiology,
Pharmaceutical,
Cardiology,
Learning,
Cardiac imaging,
ASNC,
Partnership,
Cardiac PET,
CAD,
PET,
Westin Harbour Castle Hotel,
Patient,
Physician,
Society,
Heart,
Hospital,
Jubilant Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.
Key Points:
- Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, has entered into an exclusive partnership with Cardiac Imaging, Inc., of Oakbrook Terrace, Illinois, to provide a daily-leased rubidium solution to healthcare facilities interested in performing cardiac PET.
- “This partnership with Cardiac Imaging allows unprecedented access of RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) to various types of facilities interested in performing cardiac PET,” said Sergio Calvo, President, Jubilant Radiopharma, Radiopharmaceuticals Division.
- Cardiac Imaging, Inc.’s fixed site program is a comprehensive turnkey offering, enabling physicians to administer Cardiac PET in their own facilities.
- Through these solutions, Cardiac Imaging, Inc. is advancing the field of cardiac PET and delivering premier cardiac care across the US.
Cardiology,
Radiology,
Biotechnology,
Practice Management,
Pharmaceutical,
Health,
FDA,
Hospitals,
Learning,
Society,
Society of Nuclear Medicine and Molecular Imaging,
PET,
Jubilant,
Hospital,
Patient,
McCormick Place,
Coronary artery disease,
Rest,
Medical device Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) in mobile settings.
Key Points:
- Jubilant DraxImage Inc., dba Jubilant Radiopharma, a wholly-owned subsidiary of Jubilant Pharma Limited, is pleased to announce the clearance by the FDA to use its RUBY Rubidium Elution System™ and RUBY-FILL® (Rubidium Rb82 generator) in mobile settings.
- Since the FDA approval of RUBY-FILL in 2016, Jubilant Radiopharma has partnered with health care providers across the U.S. to establish and grow cardiac PET programs.
- “The approval for mobile use with RUBY-FILL for cardiac PET is another example of Jubilant Radiopharma’s ongoing commitment to expand this imaging modality and increase patient access to this crucial test”, said Sergio Calvo, President, Jubilant Radiopharma, Radiopharmaceuticals Division.
- Additionally, if you are interested in starting a full or part time cardiac PET program, or are interested in learning more about Jubilant Radiopharma’s “RUBY Mobile Solutions” program, please visit www.RUBY-FILL.com
Research,
Medical Devices,
Medical Supplies,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
Other Science,
Science,
Lonrho,
Jubilant,
Furman University,
University,
Business,
Widener University Commonwealth Law School,
Partnership,
Darla Moore School of Business,
Journal of International Business Studies,
USD,
JHS,
Government,
Wharton School of the University of Pennsylvania,
Marketing,
GSK plc,
Privacy and the US government,
Pharmaceutical industry,
Pharma,
Chemistry Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President.
Key Points:
- Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President.
- Chris Preti has 25 years of varied pharmaceutical experience in research and development, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President.
- As previously announced in May 2022, Jubilant HollisterStier’s expansion plan that is investing ~285 million (USD) to double its capacity for fill and finish of sterile injectables at its Spokane, Washington facility, is progressing well.
- Chris Preti commented, “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide.
